Impact of disease states on the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors

Journal of Clinical Pharmacology

Volumn 46, Issue 9, 2006, Pages 968-979

  LeBlanc, Jaclyn M ^a   Dasta, Joseph F ^a   Pruchnicki, Maria C ^a   Schentag, Jerome J ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Elderly; Hepatic dysfunction; Renal dysfunction; Review

Indexed keywords

BENAZEPRIL; BENAZEPRILAT; CAPTOPRIL; CILAZAPRIL; CILAZAPRILAT; CREATINE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; FOSINOPRIL; FOSINOPRILAT; LISINOPRIL; PERINDOPRIL; PERINDOPRILAT; QUINAPRIL; QUINAPRILAT; RAMIPRIL; RAMIPRILAT; TRANDOLAPRIL; TRANDOLAPRILAT;

AGING; AREA UNDER THE CURVE; BLOOD PRESSURE REGULATION; CLINICAL PHARMACOLOGY; COMPARATIVE STUDY; CREATININE CLEARANCE; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG POTENCY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; GERIATRIC PATIENT; HUMAN; INFORMATION RETRIEVAL; KIDNEY FAILURE; LIVER FAILURE; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDLINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 33747064093     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006290333     Document Type: Review

References (84)

1. Brunner HR, Nussberger J, Waeber B. Dose-response relationships of ACE inhibitors and angiotensin II blockers. Eur Heart J. 1994;15(suppl):S123-S128.
2. White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy. 1998;18:588-599.
3. Meredith PA. Trough/peak ratios for antihypertensive agents: the issues in perspective. Drugs. 1994;48:662-666.
4. Zannad F. Duration of action of angiotensin converting enzyme inhibitors. Am J Hypertens. 1995;8:S75-S81.
5. Ajayi AA, Hockings N, Reid JL. Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Br J Clin Pharmacol. 1986;21:349-357.
6. Lees KR, Green ST, Reid JL. Influence of age on the pharmacokinetics and pharmacodynamics of perindopril. Clin Pharmacol Ther. 1988;44:418-425.
7. Resplandy G, Genissel P. Pharmacokinetics of perindopril in high-risk populations. J Cardiovasc Pharmacol. 1991;18(suppl):S9-S18.
8. Kaiser G, Ackermann R, Sioufi A. Pharmacokinetics of a new angiotensin-converting enzyme inhihitor, benazepril hydrochloride, in special populations. Am Heart J. 1989;117:746-751.
9. Sica DA. Kinetics of angiotensin-converting enzyme inhibitors in renal failure. J Cardiovasc Pharmacol. 1992;20(suppl):S13-S20.
10. Tomlinson B. Optimal dosage of ACE inhibitors in older patients. Drugs Aging. 1996;9:262-273.
11. Kelly JG, O'Malley K. Clinical pharmacokinetics of the newer ACE inhibitors. Clin Pharmacokinet. 1990;19:177-196.
12. Thind GS. Angiotensin converting enzyme inhibitors: comparative structure, pharmacokinetics, and pharmacodynamics. Cardiovasc Drugs Ther. 1990;4:199-206.
13. Belz GG, Kirch W, Kleinbloesem CH. Angiotensin-converting enzyme inhibitors: relationship between pharmacodynamics and pharmacokinetics. Clin Pharmacokinet. 1988;15(5):295-318.
14. Micromedex Healthcare Series. Greenwood Village, Colo: Thomson Micromedex (edition expires 6/2006); 2006.
15. Shionoiri H, Ueda S, Minamisawa K, et al. Pharmacokinetics and pharmacodynamics of benazepril in hypertensive patients with normal and impaired renal function. J Cardiovasc Pharmacol. 1992;20:348-357.
16. Macdonald NJ, Sioufi A, Howie CA, Wade JR, Elliott HL. The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril. Br J Clin Pharmacol. 1993;36:205-209.
17. Creasey WA, Funke PT, McKinstry DN, Sugerman AA. Pharmacokinetics of captopril in elderly healthy male volunteers. J Clin Pharmacol. 1986;26:264-268.
18. Shionoiri H, Gotoh E, Takagi N, Takeda K, Yabana M, Kaneko Y. Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal and impaired renal function. J Cardiovasc Pharmacol. 1988;11:242-249.
19. Francis RJ, Brown AN, Kler L, et al. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J Cardiovasc Pharmacol. 1987;9:32-38.
20. Meredith PA, Elliott HL, Reid JL, Francis RJ. The pharmacokinetics and angiotensin converting enzyme inhibition dynamics of cilazapril in essential hypertension. Br J Clin Pharmacol. 1989;27(suppl 2):S263-S266.
21. Williams PE, Brown AN, Rajaguru S, et al. The pharmacokinetics and bioavailability of cilazapril in normal man. Br J Clin Pharmacol. 1989;27(suppl):S181-S188.
22. Williams PE, Brown AN, Rajaguru S, Walters GE, McEwen J, Durnin C. A pharmacokinetic study of cilazapril in elderly and young volunteers. Br J Clin Pharmacol. 1989;27(suppl 2):S211-S215.
23. Hockings N, Ajayi AA, Reid JL. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Br J Clin Pharmacol. 1986;21:341-348.
24. Donnelly R, Meredith PA, Elliott HL, Reid JL. Kinetic-dynamic relations and individual responses to enalapril. Hypertension. 1990;15:301-309.
25. Gehr TW, Sica DA, Grasela DM, Fakhry I, Davis J, Duchin KL. Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients. Eur J Clin Pharmacol. 1991;41:165-169.
26. Gehr TW, Sica DA, Grasela DM, Duchin KL. The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients. Eur J Clin Pharmacol. 1993;45:431-436.
27. Shionoiri H, Minamisawa K, Ueda S, et al. Pharmacokinetics and antihypertensive effects of lisinopril in hypertensive patients with normal and impaired renal function. J Cardiovasc Pharmacol. 1990;16:594-600.
28. Lecocq B, Funck-Brentano C, Lecocq V, et al. Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum. Clin Pharmacol Ther. 1990;47:397-402.
29. Verpooten GA, Genissel PM, Thomas JR, De Broe ME. Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency. Br J Clin Pharmacol. 1991;32:187-192.
30. Lees KR, Reid JL. Effects of intravenous S-9780, an angiotensin- converting enzyme inhibitor, in normotensive subjects. J Cardiovasc Pharmacol. 1987;10:129-135.
31. Louis WJ, Workman BS, Conway EL, et al. Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjects. J Cardiovasc Pharmacol. 1992;20:505-511.
32. Elliott HL, Macdonald NJ, Meredith PA, Reid JL. Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril. Clin Pharmacol Ther. 1992;51:260-265.
33. Aurell M, Delin K, Herlitz H, Ljungman S, Witte PU, Irmisch R. Pharmacokinetics and pharmacodynamics of ramipril in renal failure. Am J Cardiol. 1987;59:65D-69D.
34. Shionoiri H, Miyakawa T, Yasuda G, et al. Pharmacokinetics of a single dose of ramipril in patients with renal dysfunction: comparison with essential hypertension. J Cardiovasc Pharmacol. 1987;10(suppl):S145-S147.
35. Witte PU, Irmisch R, Hajdu P, Metzger H. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects. Eur J Clin Pharmacol. 1984;27:577-581.
36. Debusmann ER, Pujadas JO, Lahn W, et al. Influence of renal function on the pharmacokinetics of ramipril (HOE 498). Am J Cardiol. 1987;59:70D-78D.
37. Arner P, Wade A, Engfeldt P, et al. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to young and elderly patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol. 1994;23(suppl 4):S44-S49.
38. Danielson B, Querin S, LaRochelle P, et al. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjects. J Cardiovasc Pharmacol. 1994;23(suppl 4):S50-S59.
39. Bevan EG, McInnes GT, Aldigier JC, et al. Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril. Br J Clin Pharmacol. 1993;35:128-135.
40. Dieterle WAR, Kaiser G. Pharmacokinetics of benazeprilat after intravenous administration in healthy volunteers. Eur J Clin Pharmacol. 1989;36:303A.
41. Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstry DN. Captopril kinetics. Clin Pharmacol Ther. 1982;31:452-458.
42. Singhvi SM, Duchin KL, Morrison RA, Willard DA, Everett DW, Frantz M. Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol. 1988;25:9-15.
43. Beermann B, Till AE, Gomez HJ, Hichens M, Bolognese JA, Junggren I. Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers. Biopharm Drug Dispos. 1989;10:397-409.
44. Devissaguet JP, Ammoury N, Devissaguet M, Perret L. Pharmacokinetics of perindopril and its metabolites in healthy volunteers. Fundamental Clin Pharmacol. 1990;4:175-189.
45. van Griensven JM, Schoemaker RC, Cohen AF, Luus HG, Seibert-Grafe M, Rothig HJ. Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril. Eur J Clin Pharmacol. 1995;47:513-518.
46. Greenbaum R, Zucchelli P, Caspi A, et al. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Br J Clin Pharmacol. 2000;49:23-31.
47. Schentag JJ, Nix DE, Forrest A, Adelman MH. AUIC - the universal parameter within the constraint of a reasonable dosing interval [comment]. Ann Pharmacother. 1996;30:1029-1031.
48. Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles, I: relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP. 1991;25:1050-1057.
49. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents Chemother. 1993;37:1073-1081.
50. de Leeuw PW, Hoogma RP, van Soest GA, Tchang PT, Birkenhager WH. Humoral and renal effects of MK-421 (enalapril) in hypertensive subjects. J Cardiovasc Pharmacol. 1983;5:731-736.
51. Kaiser G. Benazepril: pharmacokinetic profile in specific subpopulations. Royal Society of Medicine Services International Congress and Symposium Series. 1990;166:29-39.
52. Duchin KL, Pierides AM, Heald A, Singhvi SM, Rommel AJ. Elimination kinetics of captopril in patients with renal failure. Kidney Int. 1984;25:942-947.
53. Kripalani KJ, McKinstry DN, Singhvi SM, Willard DA, Vukovich RA, Migdalof BH. Disposition of captopril in normal subjects. Clin Pharmacol Ther. 1980;27:636-641.
54. Fillastre JP, Moulin B, Godin M, et al. Pharmacokinetics of cilazapril in patients with renal failure. Br J Clin Pharmacol. 1989;27(suppl 2):S275-S282.
55. Fruncillo RJ, Rocci ML Jr, Vlasses PH, et al. Disposition of enalapril and enalaprilat in renal insufficiency. Kidney Int Suppl. 1987;20:S117-S122.
56. Oguchi H, Miyasaka M, Koiwai T, et al. Pharmacokinetics of temocapril and enalapril in patients with various degrees of renal insufficiency. Clin Pharmacokinet. 1993;24:421-427.
57. Lowenthal DT, Irvin JD, Merrill D, et al. The effect of renal function on enalapril kinetics. Clin Pharmacol Ther. 1985;38:661-666.
58. Hui KK, Duchin KL, Kripalani KJ, Chan D, Kramer PK, Yanagawa N. Pharmacokinetics of fosinopril in patients with various degrees of renal function [comment]. Clin Pharmacol Ther. 1991;49:457-467.
59. van Schaik BA, Geyskes GG, van der Wouw PA, van Rooij HH, Porsius AJ. Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function. Eur J Clin Pharmacol. 1988;34:61-65.
60. Neubeck M, Fliser D, Pritsch M, et al. Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure: consequence of dose adjustment. Eur J Clin Pharmacol. 1994;46:537-543.
61. Halstenson CE, Opsahl JA, Rachael K, et al. The pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients with various degrees of renal function. J Clin Pharmacol. 1992;32:344-350.
62. Begg EJ, Robson RA, Bailey RR, Lynn KL, Frank GJ, Olson SC. The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment. Br J Clin Pharmacol. 1990;30:213-220.
63. Shionoiri H, Gotoh E, Sugimoto K, Takasaki I, Minamisawa K, Ishii M. Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal or impaired renal function. Br J Clin Pharmacol. 1989;27(suppl):S283-S287.
64. Kelly JG, Doyle G, Donohue J, et al. Pharmacokinetics of enalapril in normal subjects and patients with renal impairment. Br J Clin Pharmacol. 1986;21:63-69.
65. Harada AIT, Washio M. Pharmacokinetics of ramipril in chronic renal failure. Curr Ther Res. 1988;44:200-212.
66. Levinson BSA, Couchman T, Nichola P, Tu J. Advanced age per se has no influence on the kinetics of the active diacid of fosinopril [abstract]. J Clin Pharmacol. 1986;26:555.
67. Gautam PC, Vargas E, Lye M. Pharmacokinetics of lisinopril (MK521) in healthy young and elderly subjects and in elderly patients with cardiac failure. J Pharm Pharmacol. 1987;39:929-931.
68. Meyer BH, Muller FO, Badian M, et al. Pharmacokinetics of ramipril in the elderly. Am J Cardiol. 1987;59:33D-37D.
69. Gilchrist WJ, Beard K, Manhem P, Thomas EM, Robertson JI, Ball SG. Pharmacokinetics and effects on the renin-angiotensin system of ramipril in elderly patients. Am J Cardiol. 1987;59:28D-32D.
70. Kaiser G, Ackermann R, Gschwind HP, et al. The influence of hepatic cirrhosis on the pharmacokinetics of benazepril hydrochloride. Biopharm Drug Dispos. 1990;11:753-764.
71. Gross V, Treher E, Haag K, Neis W, Wiegand U, Scholmerich J. Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis: pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848). J Hepatol. 1993;17:40-47.
72. Ohnishi A, Tsuboi Y, Ishizaki T, et al. Kinetics and dynamics of enalapril in patients with liver cirrhosis. Clin Pharmacol Ther. 1989;45:657-665.
73. Baba T, Murabayashi S, Tomiyama T, Takebe K. The pharmacokinetics of enalapril in patients with compensated liver cirrhosis. Br J Clin Pharmacol. 1990;29:766-769.
74. MacLeod CMBE, Kripalani KJ, Marino MR. Effect of hepatic function on disposition of fosinopril in humans [abstract]. J Clin Pharmacol. 1990;30:839.
75. Ford NF, Natarajan C, Fulmor IE, Smith RA, Hui KK. Invasive pharmacodynamics of fosinopril in patients with congestive heart failure. J Clin Pharmacol. 1995;35:785-793.
76. Hayes PC, Plevris JN, Bouchier IA. Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function. J Hum Hypertens. 1989;3(suppl 1):S153-S158.
77. Tsai HH, Lees KR, Howden CW, Reid JL. The pharmacokinetics and pharmacodynamics of perindopril in patients with hepatic cirrhosis. Br J Clin Pharmacol. 1989;28:53-59.
78. Horvath AMOS, Ferry JJ, Hengy H, et al. Pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients with hepatic impairment [abstract]. J Clin Pharmacol. 1988;28:917.
79. Stanek B, Renner F, Sedlmayer A, Silberbauer K. Effect of captopril on renin and blood pressure in cirrhosis. Eur J Clin Pharmacol. 1987;33:249-254.
80. Louis WJ, Conway EL, Krum H, et al. Comparison of the pharmacokinetics and pharmacodynamics of perindopril, cilazapril and enalapril. Clin Exp Pharmacol Physiol Suppl. 1992;19:55-60.
81. van Schaik BA, Geyskes GG, Boer P. Lisinopril in hypertensive patients with and without renal failure. Eur J Clin Pharmacol. 1987;32:11-16.
82. Macdonald NJ, Elliott HL, Hughes DM, Reid JL. A comparison in young and elderly subjects of the pharmacokinetics and pharmacodynamics of single and multiple doses of benazepril. Br J Clin Pharmacol. 1993;36:201-204.
83. Lees KR, Reid JL. Age and the pharmacokinetics and pharmacodynamics of chronic enalapril treatment. Clin Pharmacol Ther. 1987;41:597-602.
84. Ford NF, Lasseter KC, Van Harken DR, Hammett JL, Raymond R, Manning J. Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment. J Clin Pharmacol. 1995;35:145-150.